Study #2024-1032
Phase I/IIa dose finding study of Triplet regimen of Relatlimab Ipilimumab and NIvolumab in first line therapy of metastatic melanoma (TRINITY)
MD Anderson Study Status
Enrolling
Treatment Agent
Nivolumab, Relatlimab, Ipilimumab
Description
To determine the recommended Phase IIa dose (RP2D) of the triplet combination. To determine the safety and efficacy of the combination at the RP2D.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Melanoma
Study phase:
Physician name:
Hussein Tawbi
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-581-3446
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.